Miles Williams

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

J. French, B F Williams, H. Hart et al. · BMJ · 1996 · 99 citations · Full text

A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis

Ralph Stewart, Andrew Kerr, Brett R. Cowan et al. · American Heart Journal · 2008 · 45 citations

Cardiovascular Disease, Atherosclerosis, Aldosterone-receptor Antagonist Eplerenone +9

Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow

John K. French, D. Amos, Barbara F. Williams et al. · Journal of the American College of Cardiology · 1999 · 25 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +10